Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address:
Tel:
Nycomed is a privately owned, global pharmaceutical company with headquarters in Zurich, Switzerland. The company employs 12,000 associates worldwide and has affiliates in more than 50 countries.
Nycomed has a strong presence in Europe and in the emerging markets in Russia/Commonwealth of Independent States, Asia and Latin America.
Business results and main therapeutic areas
In 2009, total sales reached € 3.2 billion, with an adjusted EBITDA of € 1.1 billion. Nycomed ranks 28th among global pharmaceutical companies and is the 16th largest provider of OTC medicines.
Nycomed’s differentiated portfolio of branded medicines is focused on gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.
Global R&D and Manufacturing presence
Research and Development is conducted at three sites in Europe and one in India. New products are sourced from our own internal Discovery organisation and in-licensed from external companies such as small biotechs. Establishing long-term partnerships is a cornerstone of Nycomed´s growth strategy.
Nycomed has 16 manufacturing sites: 5 centres of competence in Europe for global products as well as 11 production sites for regional products in fast-growing countries such as Brazil and Mexico. A major investment is being made in a new pharmaceutical plant in Russia, currently Nycomed’s biggest single market.
Nycomed provides branded medicines for hospitals, specialists and general practitioners, as well as over-the-counter (OTC) medicines. Our strong global brands complement product portfolios adapted to local preferences. Around the world, our guiding principle is to develop “medicines that matter”
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Voivodeships, Polish expenditure on health care system per one resident is still below the European average. In regards to the issue concerning the „expenditure on health care system”, I would…
Would you start by giving our readers a brief outline of the history of the PRI? In 1952 the institute was established as a research and development (R&D) centre for…
You became president of the board at Medicover in Poland only a while ago and previously your previous experience was in high-profile management but not in healthcare. Do you now…
IMS ‘lives and breathes the pharma industry’ and it is stimulating to come from other forms of consultancy to IMS. You have worked in various businesses. What motivated you to…
You were the CEO for three different companies and the founder of Sensilab and then you acquired Polfa Lodz. Could you relate to our readers the development of your career…
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Adamed was founded in 1986 by your father, Mr. Marian Adamkiewicz. The company is today still fully-owned by your family, which is remarkable in such an industry, where family-run businesses…
You joined Merck in September 1996, took gradually increasing positions at Merck, from Medical Representative (1996 – 1998), to Sales and Marketing managing positions and you were ultimately appointed Managing…
You have been appointed at the head of Pfizer Poland last December. 2010 is a hot year for the group – even very hot for some of the top management…
Apart from Poland being a 40 million population market, with double digit growth, Mr. Kuczynski of Pierre Fabre was telling us that the main opportunity of the Polish market lies…
What is PharmaExpert’s role in the Polish pharmaceutical industry? The information that PharmaExpert gathers enables us to give good insight about the evolution of the pharmacists market, the evolution of…
See our Cookie Privacy Policy Here